PPHM longs continue to promulgate the canard that accelerated approval in second-line NSCLC possible based on a phase-2 trial that missed its primary endpoint. This has never happened in FDA history, as far as I know.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”